Search

Your search keyword '"Filippatos, Gerasimos S."' showing total 227 results
Start Over Author "Filippatos, Gerasimos S." Search Limiters Peer Reviewed
227 results on '"Filippatos, Gerasimos S."'

2. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure

Author

de Koning, Marie-Sophie L. Y., Emmens, Johanna E., Romero-Hernández, Esteban, Bourgonje, Arno R., Assa, Solmaz, Figarska, Sylwia M., Cleland, John G. F., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., Metra, Marco, Filippatos, Gerasimos S., van Veldhuisen, Dirk J., Anker, Stefan D., Dickstein, Kenneth, Voors, Adriaan A., Lipsic, Erik, van Goor, Harry, and van der Harst, Pim

Published
2023
Full Text
View/download PDF

7. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2

Author

Loungani, Rahul S., Teerlink, John R., Metra, Marco, Allen, Larry A., Butler, Javed, Carson, Peter E., Chen, Chien-Wei, Cotter, Gad, Davison, Beth A., Eapen, Zubin J., Filippatos, Gerasimos S., Gimpelewicz, Claudio, Greenberg, Barry, Holbro, Thomas, Januzzi, James L., Jr., Lanfear, David E., Pang, Peter S., Piña, Ileana L., Ponikowski, Piotr, Miller, Alan B., Voors, Adriaan A., and Felker, G. Michael

Published
2020
Full Text
View/download PDF

8. International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients

Author

Burns, Daniel J.P., Arora, Jason, Okunade, Oluwakemi, Beltrame, John F., Bernardez-Pereira, Sabrina, Crespo-Leiro, Marisa G., Filippatos, Gerasimos S., Hardman, Suzanna, Hoes, Arno W., Hutchison, Stephen, Jessup, Mariell, Kinsella, Tina, Knapton, Michael, Lam, Carolyn S.P., Masoudi, Frederick A., McIntyre, Hugh, Mindham, Richard, Morgan, Louise, Otterspoor, Luuk, Parker, Victoria, Persson, Hans E., Pinnock, Claude, Reid, Christopher M., Riley, Jillian, Stevenson, Lynne W., and McDonagh, Theresa A.

Published
2020
Full Text
View/download PDF

10. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Author

Yancy, Clyde W., Jessup, Mariell, Bozkurt, Biykem, Butler, Javed, Casey, Donald E., Jr., Colvin, Monica M., Drazner, Mark H., Filippatos, Gerasimos S., Fonarow, Gregg C., Givertz, Michael M., Hollenberg, Steven M., Lindenfeld, JoAnn, Masoudi, Frederick A., McBride, Patrick E., Peterson, Pamela N., Stevenson, Lynne Warner, and Westlake, Cheryl

Published
2017
Full Text
View/download PDF

11. Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry.

Author

Abdin, Amr, Anker, Stefan D., Cowie, Martin R., Filippatos, Gerasimos S., Ponikowski, Piotr, Tavazzi, Luigi, Schöpe, Jakob, Wagenpfeil, Stefan, Komajda, Michel, and Böhm, Michael

Subjects
HEART beat, BLOOD pressure, TIME pressure, VENTRICULAR ejection fraction, HEART failure
Abstract

Aims: A high resting heart rate (RHR) and low systolic blood pressure (SBP) are a risk factor and a risk indicator, respectively, for poor heart failure (HF) outcomes. This analysis evaluated the associations between baseline RHR and SBP with outcomes and treatment patterns in patients with HF and reduced ejection fraction (HFrEF) in the QUALIFY (QUality of Adherence to guideline recommendations for LIFe‐saving treatment in heart failure surveY) international registry. Methods and results: Between September 2013 and December 2014, 7317 HFrEF patients with a previous HF hospitalization within 1–15 months were enrolled in the QUALIFY registry. Complete follow‐up data were available for 5138 patients. The relationships between RHR and SBP and outcomes were assessed using a Cox proportional hazards model and were analysed according to baseline values as high RHR (H‐RHR) ≥75 bpm versus low RHR (L‐RHR) <75 bpm and high SBP (H‐SBP) ≥110 mmHg versus low SBP (L‐SBP) <110 mmHg and analysed according to each of the following four phenotypes: H‐RHR/L‐SBP, L‐RHR/L‐SBP, H‐RHR/H‐SBP and L‐RHR/H‐SBP (reference group). Compared to the reference group, H‐RHR/L‐SBP was associated with the worst outcomes for the combined primary endpoint of cardiovascular death and HF hospitalization (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.51–2.21, p < 0.001), cardiovascular death (HR 2.70, 95% CI 1.69–4.33, p < 0.001), and HF hospitalization (HR 1.62, 95% CI 1.30–2.01, p < 0.001). Low‐risk patients with L‐RHR/H‐SBP achieved more frequently ≥50% of target doses of angiotensin‐converting enzyme inhibitors (ACEIs) and beta‐blockers (BBs) than the other groups. However, 48% and 46% of low‐risk patients were not well treated with ACEIs and BBs, respectively (≤50% of target dose or no treatment). Conclusion: In patients with HFrEF and recent hospitalization, elevated RHR and lower SBP identify patients at increased risk for cardiovascular endpoints. While SBP and RHR are often recognized as barriers that deter physicians from treating with high doses of recommended drugs, they are not the only reason leaving many patients suboptimally treated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Minimal Clinically Important Difference for Six-minute Walk Test in Patients with HFrEF and Iron Deficiency.

Author

KHAN, MUHAMMAD SHAHZEB, ANKER, STEFAN D., FRIEDE, TIM, JANKOWSKA, EWA A., METRA, MARCO, PIÑA, ILEANA L, COATS, ANDREW JS, ROSANO, GIUSEPPE, ROUBERT, BERNARD, GOEHRING, UDO-MICHAEL, DORIGOTTI, FABIO, COMIN-COLET, JOSEP, VANVELDHUISEN, DIRK J, FILIPPATOS, GERASIMOS S., PONIKOWSKI, PIOTR, BUTLER, JAVED, Piña, Ileana L, and Van Veldhuisen, Dirk J

Abstract

Background: The six-minute walk test (6MWT) is widely used to measure exercise capacity; however, the magnitude of change that is clinically meaningful for individuals is not well established in heart failure with reduced ejection fraction (HFrEF).Objective: To calculate the minimal clinically important difference (MCID) for change in exercise capacity on the 6MWT in iron-deficient HFrEF populations.Methods: In this pooled secondary analysis of FAIR-HF and CONFIRM-HF trials, mean changes in 6MWT from baseline to weeks 12 and 24 were calculated and calibrated against the Patient Global Assessment (PGA) tool [clinical anchor] to derive MCIDs for improvement and deterioration.Results: Of 760 patients included in the two trials, 6MWT and PGA data were available for 680 (89%) and 656 (86%) patients at weeks 12 and 24, respectively. The mean 6MWT distance at baseline was 281±103m. There was a modest correlation between changes in 6MWT and PGA from baseline to week 12 (r=0.31, p<0.0001) and week 24 (r=0.43, p<0.0001). Respective estimates (95% confidence intervals) for MCID in 6MWT at weeks 12 and 24 were 14m (5;23) and 15m (3;27) for a "little improvement" (vs no change), 20m (10;30) and 24m (12;36) for "moderate improvement" vs a "little improvement", -11m (-32;9.2) and -31m (-53;-8) for a "little deterioration" (vs no change), and -84m (-144;-24) and -69m (-118;-20) for "moderate deterioration" vs a "little deterioration".Conclusions: The MCID for improvement in exercise capacity on the 6MWT was 14-15m in patients with HFrEF and iron deficiency. These MCIDs can aid clinical interpretation of study data. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute Dyspnea: Results From the BACH (Biomarkers in Acute Heart Failure) Trial

Author

Maisel, Alan, Mueller, Christian, Nowak, Richard M., Peacock, W. Frank, Ponikowski, Piotr, Mockel, Martin, Hogan, Christopher, Wu, Alan H.B., Richards, Mark, Clopton, Paul, Filippatos, Gerasimos S., Di Somma, Salvatore, Anand, Inder, Ng, Leong L., Daniels, Lori B., Neath, Sean-Xavier, Christenson, Robert, Potocki, Mihael, McCord, James, Hartmann, Oliver, Morgenthaler, Nils G., and Anker, Stefan D.

Published
2011
Full Text
View/download PDF

17. Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.

Author

Inciardi, Riccardo M., Pagnesi, Matteo, Lombardi, Carlo M., Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos S., Lang, Chim C., Ng, Leong L., Pellicori, Pierpaolo, Ponikowski, Piotr, Samani, Nilesh J., Zannad, Faiez, van Veldhuisen, Dirk J., Solomon, Scott D., Voors, Adriaan A., and Metra, Marco

Subjects
HEART failure, LEFT heart atrium, HEART failure patients, ACE inhibitors, ANGIOTENSIN-receptor blockers, ATRIAL fibrillation
Abstract

Aims: Limited data exist regarding the prognostic relevance of changes in left atrial (LA) dimensions in patients with heart failure (HF). We assessed changes in LA dimension and their relation with outcomes after optimization of guideline‐directed medical therapy (GDMT) in patients with new‐onset or worsening HF. Methods and results: Left atrial diameter was assessed at baseline and 9 months after GDMT optimization in 632 patients (mean age 65.8 ± 12.1 years, 22.3% female) enrolled in BIOSTAT‐CHF. LA adverse remodelling (LAAR) was defined as an increase in LA diameter on transthoracic echocardiography between baseline and 9 months. After the 9‐month visit, patients were followed for a median of 13 further months. LAAR was observed in 247 patients (39%). Larger baseline LA diameter (odds ratio [OR] 0.90; 95% confidence interval [CI] 0.87–0.93; p < 0.001) and up‐titration to higher doses of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARBs) (OR 0.56; 95% CI 0.34–0.92; p = 0.022) were independently associated with lower likelihood of LAAR. LAAR was associated with an increased risk of the composite of all‐cause mortality or HF hospitalization (log‐rank p = 0.007 and adjusted hazard ratio 1.73, 95% CI 1.22–2.45, p = 0.002). The association was more pronounced in patients without a history of atrial fibrillation (p for interaction = 0.009). Conclusion: Among patients enrolled in BIOSTAT‐CHF, LAAR was associated with an unfavourable outcome and was prevented by ACEi/ARB up‐titration. Changes in LA dimension may be a useful marker of response to treatment and improve risk stratification in patients with HF. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

Author

Gheorghiade, Mihai, Adams, Kirkwood F., Cleland, John G.F., Cotter, Gad, Felker, G. Michael, Filippatos, Gerasimos S., Fonarow, Gregg C., Greenberg, Barry H., Hernandez, Adrian F., Khan, Sadiya, Komajda, Michel, Konstam, Marvin A., Liu, Peter P., Maggioni, Aldo P., Massie, Barry M., McMurray, John J., Mehra, Mandeep, Metra, Marco, O'Connell, John, O'Connor, Christopher M., Pang, Peter S., Piña, Ileana L., Sabbah, Hani N., Teerlink, John R., Udelson, James E., Yancy, Clyde W., Zannad, Faiez, and Stockbridge, Norman

Published
2009
Full Text
View/download PDF

22. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Ech ocardiographic, and Neu rohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomi zed C ontrolled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial

Author

Shah, Sanjiv J., Blair, John E.A., Filippatos, Gerasimos S., Macarie, Cezar, Ruzyllo, Witold, Korewicki, Jerzy, Bubenek-Turconi, Serban I., Ceracchi, Maurizio, Bianchetti, Maria, Carminati, Paolo, Kremastinos, Dimitrios, Grzybowski, Jacek, Valentini, Giovanni, Sabbah, Hani N., and Gheorghiade, Mihai

Published
2009
Full Text
View/download PDF

23. Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure

Author

Gheorghiade, Mihai, Blair, John E.A., Filippatos, Gerasimos S., Macarie, Cezar, Ruzyllo, Witold, Korewicki, Jerzy, Bubenek-Turconi, Serban I., Ceracchi, Maurizio, Bianchetti, Maria, Carminati, Paolo, Kremastinos, Dimitrios, Valentini, Giovanni, and Sabbah, Hani N.

Published
2008
Full Text
View/download PDF

27. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

Author

Senni, Michele, Paulus, Walter J., Gavazzi, Antonello, Fraser, Alan G., Díez, Javier, Solomon, Scott D., Smiseth, Otto A., Guazzi, Marco, Lam, Carolyn S. P., Maggioni, Aldo P., Tschöpe, Carsten, Metra, Marco, Hummel, Scott L., Edelmann, Frank, Ambrosio, Giuseppe, Stewart Coats, Andrew J., Filippatos, Gerasimos S., Gheorghiade, Mihai, Anker, Stefan D., Levy, Daniel, Pfeffer, Marc A., Stough, Wendy Gattis, and Pieske, Burkert M.

Published
2014
Full Text
View/download PDF

28. Exhaled Breath Condensate in Acute and Chronic Heart Failure: New Insights into the Role of Lung Injury and Barrier Dysfunction

Author

Pappas, Loukas K., Giannopoulos, Georgios, Loukides, Stelios, Gavrielatos, Gerasimos, Athanasopoulou, Efrossini, Alexanian, Ioannis P., Farmakis, Dimitrios, Korovesi, Ioanna, Letsas, Konstantinos P., Parissis, John T., Deftereos, Spyridon, Pyrgakis, Vlassis N., Kotanidou, Anastasia, Kremastinos, Dimitrios T., and Filippatos, Gerasimos S.

Published
2014
Full Text
View/download PDF

33. Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.

Author

Anker, Stefan D., Ponikowski, Piotr, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Metra, Marco, Piña, Ileana L., Coats, Andrew J.S., Rosano, Giuseppe, Dorigotti, Fabio, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., and Butler, Javed

Abstract

Aim: Improving functional capacity is a key goal in heart failure (HF). This pooled analysis of FAIR‐HF and CONFIRM‐HF assessed the likelihood of improvement or deterioration in 6‐min walk test (6MWT) among iron‐deficient patients with chronic HF with reduced ejection fraction (HFrEF) receiving ferric carboxymaltose (FCM). Methods and results: Data for 760 patients (FCM: n = 454; placebo: n = 306) were analysed. The proportions of patients receiving FCM or placebo who had ≥20, ≥30, and ≥40 m improvements or ≥10 m deterioration in 6MWT at 12 and 24 weeks were assessed. Patients receiving FCM experienced a mean (standard deviation) 31.1 (62.3) m improvement in 6MWT versus 0.1 (77.1) m improvement for placebo at week 12 (difference in mean changes 26.8 [16.6–37.0]). At week 12, the odds [95% confidence interval] of 6MWT improvements of ≥20 m (odds ratio 2.16 [1.57–2.96]; p < 0.0001), ≥30 m (2.00 [1.44–2.78]; p < 0.0001), and ≥40 m (2.29 [1.60–3.27]; p < 0.0001) were greater with FCM versus placebo, while the odds of a deterioration ≥10 m were reduced with FCM versus placebo (0.55 [0.38–0.80]; p = 0.0019). Among patients who experienced 6MWT improvements of ≥20, ≥30, or ≥40 m with FCM at week 12, more than 80% sustained this improvement at week 24. Conclusion: Ferric carboxymaltose resulted in a significantly higher likelihood of improvement and a reduced likelihood of deterioration in 6MWT versus placebo among iron‐deficient patients with HF. Of the patients experiencing clinically significant improvements at week 12, the majority sustained this improvement at week 24. These results are supportive of FCM to improve exercise capacity in HF. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.

Author

Butler, Javed, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Dorigotti, Fabio, Metra, Marco, Piña, Ileana L., Coats, Andrew J.S., Rosano, Giuseppe, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., Anker, Stefan D., and Ponikowski, Piotr

Abstract

Aim: Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron‐deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR‐HF and CONFIRM‐HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time. Methods and results: Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between‐group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least‐square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of ≥5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), ≥10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or ≥15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a ≥5‐, ≥10‐ or ≥15‐point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24. Conclusion: Treatment of iron‐deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual‐patient level; benefits were sustained over time in most patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure

Author

von Haehling, Stephan, Jankowska, Ewa A., Morgenthaler, Nils G., Vassanelli, Corrado, Zanolla, Luisa, Rozentryt, Piotr, Filippatos, Gerasimos S., Doehner, Wolfram, Koehler, Friedrich, Papassotiriou, Jana, Kremastinos, Dimitrios T., Banasiak, Waldemar, Struck, Joachim, Ponikowski, Piotr, Bergmann, Andreas, and Anker, Stefan D.

Published
2007
Full Text
View/download PDF

37. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Author

Zannad, Faiez, Garcia, Angeles Alonso, Anker, Stefan D., Armstrong, Paul W., Calvo, Gonzalo, Cleland, John G.F., Cohn, Jay N., Dickstein, Kenneth, Domanski, Michael J., Ekman, Inger, Filippatos, Gerasimos S., Gheorghiade, Mihai, Hernandez, Adrian F., Jaarsma, Tiny, Koglin, Joerg, Konstam, Marvin, Kupfer, Stuart, Maggioni, Aldo P., Mebazaa, Alexandre, Metra, Marco, Nowack, Christina, Pieske, Burkert, Piña, Ileana L., Pocock, Stuart J., Ponikowski, Piotr, Rosano, Giuseppe, Ruilope, Luis M., Ruschitzka, Frank, Severin, Thomas, Solomon, Scott, Stein, Kenneth, Stockbridge, Norman L., Stough, Wendy Gattis, Swedberg, Karl, Tavazzi, Luigi, Voors, Adriaan A., Wasserman, Scott M., Woehrle, Holger, Zalewski, Andrew, and McMurray, John J.V.

Published
2013
Full Text
View/download PDF

38. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial

Author

Möckel, Martin, Searle, Julia, Hartmann, Oliver, Anker, Stefan D, Peacock, W Frank, Wu, Alan H B, Maisel, Alan, Slagman, Anna, Ole Vollert, Jörn, Papassotiriou, Jana, Anand, Inder, Christenson, Robert, Daniels, Lori B, Filippatos, Gerasimos S., Hogan, Christopher, Morgenthaler, Nils, Mueller, Christian, Neath, Sean-Xavier, Ng, Leong, Nowak, Richard, Richards, Mark, Di Somma, Salvatore, and Ponikowski, Piotr

Published
2013
Full Text
View/download PDF

40. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

Author

Zannad, Faiez, Gattis Stough, Wendy, Rossignol, Patrick, Bauersachs, Johann, McMurray, John J.V., Swedberg, Karl, Struthers, Allan D., Voors, Adriaan A., Ruilope, Luis M., Bakris, George L., OʼConnor, Christopher M., Gheorghiade, Mihai, Mentz, Robert J., Cohen-Solal, Alain, Maggioni, Aldo P., Beygui, Farzin, Filippatos, Gerasimos S., Massy, Ziad A., Pathak, Atul, Piña, Ileana L., Sabbah, Hani N., Sica, Domenic A., Tavazzi, Luigi, and Pitt, Bertram

Published
2012
Full Text
View/download PDF

42. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial

Author

Maisel, Alan, Neath, Sean-Xavier, Landsberg, Judd, Mueller, Christian, Nowak, Richard M., Peacock, W. Frank, Ponikowski, Piotr, Möckel, Martin, Hogan, Christopher, Wu, Alan H.B., Richards, Mark, Clopton, Paul, Filippatos, Gerasimos S., Di Somma, Salvatore, Anand, Inder, Ng, Leong L., Daniels, Lori B., Christenson, Robert H., Potocki, Mihael, McCord, James, Terracciano, Garret, Hartmann, Oliver, Bergmann, Andreas, Morgenthaler, Nils G., and Anker, Stefan D.

Published
2012
Full Text
View/download PDF

43. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study

Author

Daniels, Lori B., Clopton, Paul, Potocki, Mihael, Mueller, Christian, McCord, James, Richards, Mark, Hartmann, Oliver, Anand, Inder S., Wu, Alan H.B., Nowak, Richard, Peacock, W. Frank, Ponikowski, Piotr, Mockel, Martin, Hogan, Christopher, Filippatos, Gerasimos S., Di Somma, Salvatore, Ng, Leong, Neath, Sean-Xavier, Christenson, Robert, Morgenthaler, Nils G., Anker, Stefan D., and Maisel, Alan S.

Published
2012
Full Text
View/download PDF

45. Short-term Mortality Risk in Emergency Department Acute Heart Failure

Author

Frank Peacock, W., Nowak, Richard, Christenson, Robert, DiSomma, Salvatore, Neath, Sean Xavier, Hartmann, Oliver, Mueller, Christian, Ponikowski, Piotr, Möckel, Martin, Hogan, Christopher, Wu, Alan H. B., Richards, Mark, Filippatos, Gerasimos S., Anand, Inder, Ng, Leong L., Daniels, Lori B., Morgenthaler, Nils, Anker, Stefan D., and Maisel, Alan S.

Published
2011
Full Text
View/download PDF

46. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation

Author

Piepoli, Massimo F., Conraads, Viviane, Corrà, Ugo, Dickstein, Kenneth, Francis, Darrel P., Jaarsma, Tiny, McMurray, John, Pieske, Burkert, Piotrowicz, Ewa, Schmid, Jean-Paul, Anker, Stefan D., Solal, Alain Cohen, Filippatos, Gerasimos S., Hoes, Arno W., Gielen, Stefan, Giannuzzi, Pantaleo, and Ponikowski, Piotr P.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results